RNTX advances LTI-03 in Phase 2 IPF trials, enrolls RENEW
RNTX says its inhaled peptide LTI-03 has shown favorable safety and biomarker activity, and is advancing in Phase 2 for IPF. The RENEW Phase 2 trial is now enrolling, with data expected in late 2026.
LTI-03, a novel inhaled peptide, showed strong antifibrotic and regenerative effects in preclinical and early clinical studies, with a favorable safety profile and biomarker activity. Original document: Rein Therapeut…